Literature DB >> 1967486

Class II MHC molecules can use the endogenous pathway of antigen presentation.

J G Nuchtern1, W E Biddison, R D Klausner.   

Abstract

Models for antigen presentation have divided the world of antigens into two categories, endogenous and exogenous, presented to T cells by class I and class II major histocompatibility complex (MHC) encoded molecules, respectively. Exogenous antigens are though to be taken up into peripheral endosomal compartments where they are processed for binding to class II MHC molecules. Endogenous antigens are either synthesized or efficiently delivered to the cytoplasm before being partially degraded in an as yet undefined way, and complexed with class I MHC molecules. A useful phenotypic distinction between the two pathways has been the sensitivity to weak bases, such as chloroquine, which is a property only of the exogenous pathway. The fungal antibiotic brefeldin A (BFA), which blocks protein transport from the endoplasmic reticulum to the Golgi network, also blocks class I-restricted antigen-presentation, providing us with the corresponding marker of the endogenous pathway. Experiments with influenza virus antigens have supported the view that class II MHC molecules can present exogenous but not endogenous antigen, whereas the observation that class II MHC molecules present measles virus non-membrane antigens by a chloroquine-insensitive pathway suggests that this is not always the case. We show here that influenza A matrix protein can be effectively presented to class II-restricted T cells by two pathways: one of which is chloroquine-sensitive, BFA-insensitive, the other being chloroquine-insensitive and BFA-sensitive. Our results indicate that both class I and class II molecules can complex with antigenic peptides in a pre-Golgi compartment and favour a unified mechanism for MHC-restricted endogenous antigen presentation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967486     DOI: 10.1038/343074a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  57 in total

Review 1.  Beyond the classical: influenza virus and the elucidation of alternative MHC class II-restricted antigen processing pathways.

Authors:  Laurence C Eisenlohr; Nancy Luckashenak; Sebastien Apcher; Michael A Miller; Gomathinayagam Sinnathamby
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

Review 2.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

3.  Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules.

Authors:  P A Roche; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 4.  Cellular mechanisms of antigen processing and the function of class I and II major histocompatibility complex molecules.

Authors:  C V Harding; E R Unanue
Journal:  Cell Regul       Date:  1990-06

5.  Class II-restricted presentation of an endogenously derived immunodominant T-cell determinant of hen egg lysozyme.

Authors:  A Brooks; S Hartley; L Kjer-Nielsen; J Perera; C C Goodnow; A Basten; J McCluskey
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

6.  Alternative endogenous protein processing via an autophagy-dependent pathway compensates for Yersinia-mediated inhibition of endosomal major histocompatibility complex class II antigen presentation.

Authors:  Holger Rüssmann; Klaus Panthel; Brigitte Köhn; Stefan Jellbauer; Sebastian E Winter; Sara Garbom; Hans Wolf-Watz; Sigrid Hoffmann; Silke Grauling-Halama; Gernot Geginat
Journal:  Infect Immun       Date:  2010-09-27       Impact factor: 3.441

Review 7.  Self determinant selection and acquisition of the autoimmune T cell repertoire.

Authors:  G Benichou; R C Tam; P I Orr; M R Garovoy; E V Fedoseyeva
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

8.  Processing of the DRB1*1103-restricted measles virus nucleoprotein determinant 185-199 in the endosomal compartment.

Authors:  S Demotz; W Ammerlaan; P Fournier; C P Muller; C Barbey
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

9.  Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras.

Authors:  T Gedde-Dahl; E Nilsen; E Thorsby; G Gaudernack
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

10.  Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice.

Authors:  S Tourne; H M van Santen; M van Roon; A Berns; C Benoist; D Mathis; H Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.